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Abstract
Background: Inclusions of TAR DNA binding protein-43 (TDP-43) are the defining histopathological feature of
several neurodegenerative diseases collectively referred to as TDP-43 proteinopathies. These diseases are
characterized by the presence of cellular aggregates composed of abnormally phosphorylated, N-terminally
truncated and ubiquitinated TDP-43 in the spinal cord and/or brain. Recent studies indicate that C-terminal
fragments of TDP-43 are aggregation-prone and induce cytotoxicity. However, little is known regarding the
pathways responsible for the degradation of these fragments and how their phosphorylation contributes to the
pathogenesis of disease.
Results: Herein, we established a human neuroblastoma cell line (M17D3) that conditionally expresses an
enhanced green fluorescent protein (GFP)-tagged caspase-cleaved C-terminal TDP-43 fragment (GFP-TDP220-414).
We report that expression of this fragment within cells leads to a time-dependent formation of inclusions that are
immunoreactive for both ubiquitin and phosphorylated TDP-43, thus recapitulating pathological hallmarks of
TDP-43 proteinopathies. Phosphorylation of GFP-TDP220-414 renders it resistant to degradation and enhances its
accumulation into insoluble aggregates. Nonetheless, GFP-TDP220-414 inclusions are reversible and can be cleared
through the ubiquitin proteasome system. Moreover, both Hsp70 and Hsp90 bind to GFP-TDP220-414 and regulate
its degradation.
Conclusions: Our data indicates that inclusions formed from TDP-43 C-terminal fragments are reversible. Given
that TDP-43 inclusions have been shown to confer toxicity, our findings have important therapeutic implications
and suggest that modulating the phosphorylation state of TDP-43 C-terminal fragments may be a promising
therapeutic strategy to clear TDP-43 inclusions.
Background
Inclusions of TAR DNA binding protein-43 (TDP-43)
are the defining histopathological feature of frontotem-
poral lobar degeneration with ubiquitin-positive inclu-
sions (FTLD-U) and amyotrophic lateral sclerosis (ALS)
[1,2]. Under physiological conditions, TDP-43 predomi-
nantly localizes to the nucleus. However, a substantial
loss of nuclear TDP-43 is observed in neurons bearing
aberrant cytoplasmic TDP-43 inclusions. TDP-43 exhi-
bits a disease-specific biochemical signature; pathologi-
cally altered TDP-43 is ubiquitinated, phosphorylated
and cleaved to generate C-terminal fragments of
24-26 kDa [1,2].
Recent findings have shown that TDP-43 C-terminal
fragments form cytoplasmic aggregates and cause cyto-
toxicity [3-6]; thus, TDP-43 truncation may play an
important role in the pathogenesis of ALS, FTLD-U and
other TDP-43 proteinopathies. TDP-43 is a substrate of
caspases, as shown by our and others’ work, suggesting
that caspase-cleaved TDP-43 may account for some of
the C-terminal fragments observed in disease [7-9].
Furthermore, three other C-terminal fragments (amino
acid residues 208-414, 219-414 and 247-414) have been
identified in FTLD-U brain tissue [4,5]. Although the
cleavage sites of these reported C-terminal TDP-43 frag-
ments are not identical, they may share similar
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C-terminal fragments in cell culture systems induces
cytotoxicity [3] and recapitulates pathological features of
disease, including TDP-43 ubiquitination, phosphoryla-
tion and cytoplasmic aggregation [3-5]. Of particular
interest, the ubiquitination of C-terminal TDP-43 frag-
ments suggests that they are degraded through the ubi-
quitin-proteasome system (UPS). Despite recent studies
that support the notion that full-length and cleaved
TDP-43 are degraded via the UPS as well as by autop-
hagy [10-12], our understanding of TDP-43 clearance
remains limited.
The hyperphosphorylation of aggregated proteins is a
common feature of many neurodegenerative diseases.
For instance, the microtubule-associated protein tau is
abnormally phosphorylated in Alzheimer’s disease as is
a-synuclein in Parkinson’s disease. It is believed that an
imbalance of kinase and phosphatase activity contributes
to the abnormal phosphorylation state of tau, which
impairs the normal functioning of tau while inhibiting
its degradation and facilitating its assembly into paired
helical filaments [13]. With regards to TDP-43, little is
currently known regarding how phosphorylation affects
TDP-43 degradation and aggregation. Recently, it has
been shown that the in vitro phosphorylation of recom-
binant full-length TDP-43 by casein kinases enhances
TDP-43 oligomerization and fibrillization [14]. However,
w ea n do t h e r sh a v ed e m o n s t r a t e dt h a tp h o s p h o r y l a t i o n
of TDP-43 C-terminal fragments at disease-specific sites
is not necessary for inclusion formation in cells [3,9].
Even though phosphorylation does not appear to be a
requirement for TDP-43 aggregation, it is not yet
known if it would accelerate aggregate formation in cells
as it does in vitro.
To bridge this gap in our understanding, we generated
a human neuroblastoma cell line (M17D3) that condi-
tionally expresses an enhanced green fluorescent protein
(GFP)-tagged caspase-cleaved C-terminal TDP-43 frag-
ment (GFP-TDP220-414), and we examined how the
phosphorylation state of GFP-TDP220-414 impacts its
solubility, aggregation and degradation. We found that
the gradual expression of GFP-TDP220-414 within cells
caused the formation of cytoplasmic inclusions that
were immunoreactive for both ubiquitin and phosphory-
lated TDP-43. Of great significance, we found that these
inclusions could be cleared through the UPS, although
phosphorylation of TDP-43 C-terminal fragments
delayed their degradation. Knocking-down the expres-
sion of heat shock proteins (Hsp), Hsp70 or Hsp90,
impaired the clearance of GFP-TDP220-414 and led to
the preferential accumulation of phosphorylated species,
which suggests that the Hsp90/Hsp70-based chaperone
machinery regulates the degradation of phosphorylated
C-terminal TDP-43 fragments. Our findings provide
novel insight into understanding how phosphorylation
affects the degradation and aggregation of TDP-43
C-terminal fragments. Furthermore, given that TDP-43
inclusions have been shown to confer toxicity [3,6,15],
our evidence that such inclusions can be cleared from
cells has important therapeutic implications.
Results
TDP-43 C-terminal fragments share similar pathological
properties
In TDP-43 proteinopathies, TDP-43 is cleaved to gener-
ate C-terminal fragments [1]. Given that TDP-43 trun-
cation and phosphorylation are only observed in
affected brain and spinal cord regions, these modifica-
tions are believed to contribute to the pathogenesis of
disease. To test whether various TDP-43 fragments
share similar pathological properties in cells, three TDP-
43 C-terminal fragments tagged at the amino terminal
with enhanced GFP (GFP-TDP208-414,G F P - T D P 220-414
and GFP-TDP247-414) were transiently expressed in
human neuroblastoma M17 cells and compared to the
expression of full-length TDP-43. The transient expres-
sion of GFP alone, full-length TDP-43 and all three frag-
ments resulted in a similar level of protein expression
(Figure 1A). Full-length GFP-TDP-43 was expressed dif-
fusely within the nucleus of cells whereas the C-terminal
TDP-43 fragments formed compact cytoplasmic inclu-
sions (Figure 1B), which is consistent with previous
reports [3-5]. We observed similar inclusions following
the transient expression of untagged TDP220-414 (not
shown), indicating that inclusion formation was not
merely due to the GFP tag. Note that only TDP-43 frag-
ments were phosphorylated at pathologically specific
sites (serine 409 and serine 410) [14]. Of interest, the
expression of GFP-TDP208-414, GFP-TDP220-414 and
GFP-TDP247-414, but not that of GFP-TDP-43, appeared
to moderately induce the molecular chaperone Hsp70
(Figure 1A), suggesting that inclusion formation may
induce a stress response in cells. In contrast, no obvious
change in the ratio between uncleaved (LC3B-I) and
cleaved (LC3B-II) LC3B, a common indicator of autop-
hagy [16], was observed among samples (Figure 1A).
B a s e do nt h e s ef i n d i n g s ,w eg e n e r a t e das t a b l ec e l ll i n e
that conditionally expresses the C-terminal fragment
corresponding to caspase-cleaved TDP-43 (GFP-TDP220-
414) in order to study how phosphorylation influences
degradation and inclusion formation of TDP-43 C-term-
inal fragments.
Inducible expression of TDP-43 C-terminal fragment
recapitulates pathological hallmarks of TDP-43
proteinopathies
By using a tetracycline-off inducible gene expression sys-
tem, we produced a stable human neuroblastoma cell
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Page 2 of 13line (termed M17D3) that inducibly expresses GFP-
TDP220-414 in the absence of doxycycline, a tetracycline
derivative. No GFP-TDP220-414 was expressed in cells
when doxycycline was present (Figure 2A and 2B), con-
firming that GFP-TDP220-414 expression was tightly
regulated. To test whether gradual expression of GFP-
TDP220-414 mimics the aggregation process in disease,
M17D3 cells were grown in doxycycline-free media for
2, 4, 6 or 8 days; this led to a time-dependent expression
of GFP-TDP220-414 (Figure 2A). GFP-TDP220-414 was
phosphorylated at S409/S410 as early as 2 days post-
induction, with levels increasing noticeably by day 8
(Figure 2A). By 6 days of induction, high-molecular
weight (HMW) TDP-43-immunoreactive products were
observed. These HMW species may be a product of
GFP-TDP220-414 oligomerization or the result of other
types of modifications, such as cross-linking (Figure 2A).
The appearance of the HMW products and the
formation of large cytoplasmic inclusions (Figure 2B)
coincided with an increase in the expression of Hsp70
( F i g u r e2 A ) .C l e a v a g eo fL C 3 B ,h o w e v e r ,w a sn o te v i -
dent at any time-point post-induction (Figure 2A).
Fluorescent confocal microscopy revealed that numer-
ous small cytoplasmic inclusions were observed within
cells as early as 2 days following the induction of GFP-
TDP220-414 (Figure 2B). The lack of diffuse GFP fluores-
cence at this time-point highlights the high propensity
for GFP-TDP220-414 to aggregate upon expression. At
later time-points, larger, but fewer, inclusions were pre-
sent per cell, suggesting that the larger inclusions were
formed by the assembly of small inclusions (Figure 2B).
In addition, the larger inclusions at day 6 were intensely
stained by antibodies for ubiquitin and pTDP-43
(Ser409/410), suggesting that GFP-TDP220-414 within
inclusions is phosphorylated and ubiquitinated (Figure
2C). To definitively determine if GFP-TDP220-414 is
B A
GFP
GFP-TDP-43
GFP-TDP208-414
GFP-TDP220-414
GFP-TDP247-414
GFP
pTDP-43
Hsp70
LC3B
GAPDH
I
II
80
60
50
40
30
20
80
60
50
40
30
80
60
20
40
GFP GFP-TDP-43 GFP-TDP208-414
GFP-TDP220-414 GFP-TDP247-414
Figure 1 TDP-43 C-terminal fragments share similar pathological properties, such as phosphorylation and aggregation. M17 cells were
transiently transfected to express GFP, GFP-TDP-43 or various GFP-TDP-43 C-terminal fragments for 2 days. (A) Western blotting of cell lysates
using a phosphorylation-dependent (pS409/pS410) TDP-43 antibody (termed pTDP-43) or antibodies towards GFP, Hsp70, LC3B and GAPDH; the
latter antibody was used to verify protein loading. (B) GFP fluorescence in cells expressing GFP, GFP-TDP-43 or GFP-tagged C-terminal fragments
of TDP-43 was viewed by fluorescent confocal microscopy. Scale bar, 10 μM. Figures shown are representative of the results obtained from 2
independent experiments.
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Figure 2 Time-dependent expression and aggregation of GFP-TDP220-414 in M17D3 cells. M17D3 cells were cultured in media lacking or
containing 1 μg/ml doxycycline to either induce or suppress the expression of GFP-TDP220-414, respectively. (A) The expression of total and
phosphorylated-GFP-TDP220-414 were assessed using antibodies towards the C-terminus of TDP-43 (cTDP-43) or anti-pTDP-43, respectively.
Endogenous TDP-43 is indicated by an asterisk (*) while dashed arrows indicate TDP-43 fragments, which likely resulted from the truncation of GFP-
TDP220-414. HMW=high-molecular weight, NS = non-specific band, Dox=doxycycline. (B) GFP fluorescence in cells expressing GFP-TDP220-414 was
viewed by fluorescent confocal microscopy at 2, 4 and 6 days post-induction and in non-induced controls. Scale bar, 20 μM. (C) GFP-TDP220-414-
expressing cells were immunostained with antibodies towards S409/S410-phosphorylated TDP-43 or ubiquitin. Scale bar, 10 μM. Figures shown are
representative of the results obtained from 4 independent experiments. (D) M17 founder cells were cotransfected for 48 h with HA-ubiquitin and
GFP or GFP-TDP220-414. Cell lysates were incubated with anti-GFP. Protein G agarose was added to capture the protein-antibody complex and then
the captured protein was eluted from the beads and resolved by SDS-PAGE for Western blot analysis. Blots were probed with antibodies towards
the HA-tag or GFP. Figures shown are representative of the results obtained from 3 independent experiments.
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Page 4 of 13ubiquitinated, cells were transiently co-transfected to
express HA-ubiquitin and GFP-TDP220-414 or GFP. Two
days post-transfection, a GFP-antibody was used to
immuoprecipitate GFP-TDP220-414 or GFP from cell
lysates. Although both GFP and GFP-TDP220-414 were
pulled down efficiently under these experimental condi-
tions, only GFP-TDP220-414 was ubiquitinated (Figure
2D). These findings indicate that inducible expression of
GFP-TDP220-414 recapitulates pathological hallmarks of
TDP-43 proteinopathies.
TDP-43 C-terminal fragment is preferentially degraded
through the ubiquitin-proteasome system
To monitor GFP-TDP220-414 clearance and to assess if
inclusions, once formed, can be degraded, cells were
induced to express GFP-TDP220-414 for 5 days and then
exposed to doxycycline to block transgene expression
for 1 day thereafter. As a control, sister-cultures were
grown in doxycycline-free media to maintain GFP-
TDP220-414 expression for the duration of the 6-day
experiment. As expected, GFP-TDP220-414 was highly
expressed (Figure 3A), and many inclusions were pre-
sent in these control cultures (Figure 3B). Conversely, a
marked decrease in protein level of GFP-TDP220-414
(Figure 3A) and in the number of inclusion-bearing cells
(Figure 3B) were observed in cultures that were treated
with doxycycline on day 5. The degradation of GFP-
TDP220-414 was completely suppressed by the protea-
some inhibitor, MG-132 (Figure 3A and 3B). Interest-
ingly, inclusions in MG-132-treated cells were larger
than those in control cells, suggesting that blocking the
degradation of GFP-TDP220-414, and consequently pro-
moting the accumulation of phosphorylated GFP-
TDP220-414, increases the rate of inclusion assembly. In
contrast to MG-132, neither the lysosomal inhibitors,
chloroquine and NH4Cl, nor the autophagy inhibitor,
3-MA, appreciably blocked the degradation of GFP-
TDP220-414 (Figure 3A and 3B) indicating that this TDP-
43 C-terminal fragment is preferentially degraded via
the UPS.
To determine whether the targeting of GFP-TDP220-414
to the proteasome for degradation was dependent upon
its fusion to GFP, M17D Tet-Off founder cells were
made to transiently express GFP-TDP220-414 or GFP.
Compared to cells expressing GFP-TDP220-414 for 2 days,
the level of GFP-TDP220-414 was noticeably decreased in
cells treated with doxycycline to suppress GFP-TDP220-
414 expression during the second day of the 2-day experi-
ment (Figure 3C). However, if the proteasome was inhib-
ited by MG-132, GFP-TDP220-414 degradation was
suppressed (Figure 3C). In contrast, GFP levels remained
unchanged even when GFP expression was blocked dur-
ing the second of the 2 day experiment (Figure 3C).
These results indicate that the proteasomal degradation
of GFP-TDP220-414 is not due to the targeting of GFP to
the proteasome.
Knockdown of heat shock proteins leads to the
accumulation of TDP-43 C-terminal fragment
Hsp70 and Hsp90 play critical roles in protein quality
control. In Alzheimer’sd i s e a s ea n dH u n t i n g t o n ’sd i s -
ease, these chaperones bind to tau or mutant hunting-
ton protein, respectively, and target these aggregation-
prone proteins to the proteasome for degradation
[17,18]. Given these findings and the fact that Hsp70
protein levels were increased by the expression of TDP-
43 C-terminal fragments (Figs. 1A and 2A), we tested
whether Hsp90 and Hsp70 bind GFP-TDP220-414 and
mediate its degradation. Immuoprecipitation studies
i n d i c a t e dt h a tG F P - T D P 220-414,b u tn o tG F P ,b i n d
Hsp70 and Hsp90 (Figure 4A). In order to investigate if
the proteasomal degradation of GFP-TDP220-414 is
mediated by its interaction with Hsp90 or Hsp70, cells
were incubated in doxycycline-free media for 4 days fol-
l o w e db ya2d a yt r e a t m e n tw i t hs i R N A st a r g e t e dt o
Hsp90 or Hsp70. This led to a decrease in Hsp90 and
Hsp70 protein expression by 34% and 60%, respectively
(Figure 4B and 4C). Decreasing Hsp70 or Hsp90 expres-
sion resulted in increased levels of GFP-TDP220-414,a s
assessed using both phosphorylation-independent and
-dependent TDP-43 antibodies (Figure 4B). Compared
to GFP-TDP220-414 in cells treated with non-silencing
siRNA, total and phosphorylated GFP-TDP220-414 levels
were elevated by approximately 1.3-fold and 2.8-fold,
respectively, in cells treated with Hsp90 siRNA (Figure
4C). In a similar fashion, Hsp70 siRNA treatment led to
1.5-fold and 2.5-fold increase in total and phosphory-
lated GFP-TDP220-414, respectively (Figure 4C). More
important, compared to the 30-50% increase in total
GFP-TDP220-414 resulting from Hsp90 or Hsp70 knock-
down, phosphorylated-GFP-TDP220-414 levels were sig-
nificantly increased by nearly 150-180% (Figure 4C).
These results suggest that Hsp70 and Hsp90 preferen-
tially facilitate the degradation of phosphorylated
C-terminal fragments and that impairment of the
Hsp70/Hsp90/GFP-TDP220-414 complex leads to the
accumulation of phosphorylated-GFP-TDP220-414.
Phosphorylated TDP-43 C-terminal fragment is resistant
to proteasomal degradation
To further assess how phosphorylation influences the
degradation of truncated TDP-43, GFP-TDP220-414 was
inducibly expressed for 5 days, at which point 1 μg/ml
doxycycline was added to the medium to halt transgene
e x p r e s s i o n .C e l l sw e r eh a r v e s t e da t0 ,6 ,1 2 ,1 8o r2 4
hours after the addition of doxycycline for Western blot
analysis of total GFP-TDP220-414 and phosphorylated-
GFP-TDP220-414 (Figure 5A). The amount of total or
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Figure 3 The TDP-43 C-terminalf r a g m e n t ,G F P - T D P 220-414, is preferentially degraded through the ubiquitin-proteasome pathway.
To monitor GFP-TDP220-414 degradation, M17D3 were grown in doxycycline-free media for 5 days to induce GFP-TDP220-414 expression. Its
expression was then inhibited by doxycycline and cells were treated with the proteasome inhibitor, MG-132, the lysosome inhibitors, chloroquine
(CQ) or NH4Cl, or the autophagy inhibitor, 3-MA. Control cultures were maintained in doxycycline-free media to sustain GFP-TDP220-414 expression.
On day 6, cells were harvested for Western blot analysis and confocal microscopy. (A) Blots were probed using an anti-cTDP-43, anti-pTDP-43 and
anti-GAPDH antibodies. The arrow indicates GFP-TDP220-414, the asterisk (*) endogenous TDP-43, and the dashed arrows cleavage products, likely
resulting from GFP-TDP220-414 truncation. Dox=doxycycline, HMW = high molecular weight, NS=non-specific. (B) GFP fluorescence in cells after 6
days of GFP-TDP220-414 induction in doxycycline-free media (CTRL) was compared to that in cells treated with doxycycline during the last 24 h of
the 6-day experiment (Dox) or to cells co-treated with doxycycline and MG-132 (Dox+MG-132), chloroquine (Dox+CQ), or 3-MA (Dox+3-MA). Scale
bars, 20 μM (10 μM in inset). (C) To determine if the GFP-tag is responsible for targeting GFP-TDP220-414 to the proteasome for degradation, M17D
cells were transfected with pTRE-GFP or pTRE-GFP-TDP220-414 for 2 days. During these 2 days, cultures were treated with or without doxycycline and
MG-132, as indicated. Cells were then harvested for Western blot analysis using anti-GFP and anti-GAPDH. GFP-TDP220-414, but not GFP, was
degraded by the proteasome. Figures shown are representative of the results obtained from 3 independent experiments.
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Page 6 of 13phosphorylated GFP-TDP220-414 remaining in the lysates
at each time-point was normalized to the amount pre-
sent at the time doxycycline was added (t = 0). Of inter-
est, phosphorylated-GFP-TDP220-414 was cleared from
cells more slowly than total GFP-TDP220-414 (t1/2 = 22.1
hours vs. 14.2 hours, respectively; Figure 5A and 5B).
To characterize the solubility of phosphorylated-GFP-
TDP220-414, cell lysates were separated into Triton X-
100-soluble and -insoluble fractions and analyzed by
Western blotting. While the majority of total GFP-
TDP220-414 (~57%) was concentrated in the detergent
soluble fraction (Figure 5C and 5D), the opposite was
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Figure 4 Knockdown of heat shock proteins leads to the accumulation of TDP-43 C-terminal fragments. (A) Co-immunoprecipitation
studies showed that GFP-TDP220-414, but not GFP, binds to Hsp70 and Hsp90. M17 founder cells expressing HA-ubiquitin and GFP or GFP-TDP220-
414 were harvested and lysates were incubated with anti-GFP. Protein G agarose was added to capture the protein-antibody complex and the
captured protein was eluted from the beads and resolved by SDS-PAGE for Western blot analysis. Blots were probed with antibodies towards
GFP, Hsp70 or Hsp90 (note that blots were also probed with an antibody toward the HA-tag, which is shown in Figure 2D). Figures shown are
representative of the results obtained from 3 independent experiments. (B-C) To explore the role of Hsp70 and Hsp90 in the degradation of
GFP-TDP220-414, M17D3 cells were grown in doxycycline-free medium for 4 days then treated with siRNA targeted to Hsp90 or Hsp70 or with a
validated negative siRNA control. After 48 h, cells were harvested for Western blot analysis using the indicated antibodies. Levels of total TDP-43,
phosphorylated TDP-43, Hsp70 and Hsp90 were determined by densitometric analysis (C). Data was collected from 3 separate experiments and
shown as the mean ± SEM. ** represents P < 0.001, as assessed by 1-way ANOVA, followed by Tukey’s posthoc analysis.
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Figure 5 Phosphorylated TDP-43 C-terminal fragment is resistant to proteasomal degradation. To calculate the half-life of GFP-TDP220-414,
cells were maintained in doxycycline-free media for 5 days. Doxycycline (1 μg/ml) was then added to the media to arrest GFP-TDP220-414
expression. Cells were harvested immediately (0 hours) as well as 6, 12, 18 and 24 hours after the addition of doxycycline. (A) Western blot
analysis of cell lysates using antibodies towards the C-terminus of TDP-43 (cTDP-43) or phosphorylated TDP-43 (pTDP-43). The arrow indicates
GFP-TDP220-414, the asterisk (*) endogenous TDP-43, and the dashed arrows cleavage products, likely generated from the truncation of GFP-
TDP220-414.. Dox=doxycycline, NS=non-specific. (B) Densitometric quantification of GFP-TDP220-414 in cells was calculated by dividing the density
of bands for total or phosphorylated GFP-TDP220-414 by that of the corresponding GAPDH band, then normalizing each time-point to GFP-
TDP220-414/GAPDH levels at 0 hours. The half life (T1/2) of total GFP-TDP220-414 was 14.2 hours; T1/2 for phospho-GFP-TDP220-414 was 22.1 hours.
** represents P<0.001, as assessed by 1-way ANOVA, followed by Tukey’s posthoc analysis (n = 3). (C) To examine the solubility of total and
phosphorylated-GFP-TDP220-414, M17D3 cells were incubated in doxycycline-free media for 6 days. Cell lysates were separated into Triton X-100-
soluble (TS) and -insoluble (TIS) fractions and analyzed by Western blotting using anti-GFP and anti-pTDP-43 antibodies. (D) Densitometric
quantification of total and phosphorylated GFP-TDP220-414 in the Triton X-100-soluble and -insoluble fractions. Data was collected from 3 separate
experiments and is shown as the mean+SEM.
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two percent of phosphorylated-GFP-TDP220-414 accumu-
lated in the detergent insoluble fraction (Figure 5C and
5D). These findings suggest that phosphorylation ren-
ders GFP-TDP220-414 resistant to proteasomal degrada-
tion and decreases its solubility.
Discussion
In ALS, FTLD-U, as well as other TDP-43 proteinopa-
thies, the presence of TDP-43-positive inclusions within
affected neurons and glia is accompanied by abnormal
TDP-43 ubiquitination, phosphorylation and cleavage to
generate C-terminal fragments [1]. Since C-terminal
fragments of TDP-43 are recovered in the sarkosyl-inso-
luble fraction of brain and spinal cord homogenates of
diseased patients, it has been hypothesized that they
serve to seed TDP-43 aggregation and play an important
role in disease pathogenesis. Recently, we and others
have demonstrated that transient expression of TDP-43
C-terminal fragments within cells causes the formation
of cytoplasmic inclusions [3-5]. Such an approach
results in very high expression levels of the exogenous
protein during a relatively short time period. In the pre-
sent study, we used a tetracycline-inducible model to
determine whether a more gradual expression of cas-
pase-cleaved TDP-43 C-terminal fragments (GFP-
TDP220-414) also leads to inclusion formation. By slowing
the time-course over which inclusions are formed, we
were able to investigate the aggregation process in more
detail. It is important to note that numerous small cyto-
plasmic inclusions were observed within cells as early as
2 days following the induction of GFP-TDP220-414 (Fig-
ure 2). Minor diffuse GFP fluorescence was observed at
this time-point underscoring the high propensity of
GFP-TDP220-414 to aggregate upon expression. At later
time-points, larger, but fewer, inclusions were present
per cell, indicating that large inclusions are formed by
the assembly of small inclusions (Figure 2). The pre-
sence of large cytoplasmic inclusions at day 6, as
assessed by immunofluorescence studies, coincide with
the induction of Hsp70, as assessed by Western Blot
(Figure 2), suggesting that inclusion formation induces a
heat shock response. Since we found that Hsp70, as well
as Hsp90, play a role in regulating GFP-TDP220-414
degradation (Figure 4), the induction of Hsp70 may be
an attempt made by cells to promote the clearance of
GFP-TDP220-414 once levels reach a harmful threshold.
Indeed, it is becoming increasingly apparent that C-
terminal TDP-43 fragments are toxic. We have pre-
viously shown that the aggregation of these fragments is
associated with increased cytotoxicity, which likely
results from a toxic gain of function since GFP-TDP220-
414 inclusion formation neither alters the nuclear distri-
bution of endogenous full-length TDP-43, nor does it
reduce its function, as assessed using an exon skipping
assay [3]. In addition, studies conducted in yeast have
shown that TDP-43 species that form aggregates are
toxic and that the C-terminal region of TDP-43 is
required for both aggregation and toxicity [6].
The ubiquitination of TDP-43 inclusions in disease
[1,2] suggests that full-length and/or truncated TDP-43
are substrates of the UPS. Consistent with our findings,
recent studies have shown that full-length TDP-43 and
TDP-43 fragments are ubiquitinated [11,12] and can be
cleared by the UPS [11,12] and autophagy [10-12] in
cultured cells. However, the earlier studies did not
examine the molecular determinants of TDP-43 degra-
dation, such as TDP-43 phosphorylation, as done in the
present study. To better understand the degradation
pathways of C-terminal TDP-43 fragments, we took
advantage of our inducible cell model and the fact that
transcription of GFP-TDP220-414 could be inhibited by
the addition of doxycycline. The latter point is impor-
tant since studies have shown that proteasomal inhibi-
tors cause transcriptional up-regulation of the
cytomegalovirus (CMV) promoter [19,20], which was
used to drive expression of TDP-43 products in the pre-
s e n ts t u d ya n dt h es t u d yc o n d u c t e db yW a n ge ta l .
(2010), who previously reported that TDP-43 accumu-
lates following proteasomal inhibition [11]. Because dox-
ycycline blocks transcription of GFP-TDP220-414 in our
inducible cell model, it is ideally suited to assess steady-
state levels of GFP-TDP220-414 and how GFP-TDP220-414
protein levels are affected upon treatment with protea-
some inhibitors. Our findings indicate that GFP-TDP220-
414 was ubiquitinated and markedly accumulated when
cells were treated with the proteasome inhibitor, MG-
132. In contrast, only modest increases in GFP-TDP220-
414 were observed following inhibition of the autopha-
gic-lysosomal pathway. The accumulation of GFP-
TDP220-414 upon proteasome inhibition was specific,
s i n c eG F P ,u n l i k eG F P - T D P 220-414, did not accumulate
during MG-132 treatment. These findings suggest that
C-terminal TDP-43 fragments are degraded predomi-
nantly through the UPS (Figure 2 and 4).
Most important, our data indicates that, at the time-
points examined, inclusion formation is reversible if the
overexpression of GFP-TDP220-414 is halted. The clear-
ance of inclusions is due to proteasome-mediated degra-
dation of GFP-TDP220-414 since proteasomal inhibition,
but not lysosomal/autophagy inhibition, prevents inclu-
sion clearance. While both total GFP-TDP220-414 and
phosphorylated-GFP-TDP220-414 were degraded when
GFP-TDP220-414 was suppressed, it is noteworthy that
the half-life of phosphorylated GFP-TDP220-414 was
longer than that of total GFP-TDP220-414. Moreover, the
majority of phosphorylated GFP-TDP220-414 within cells
was insoluble. While we have previously reported that
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gate [3], our present findings suggest that phosphoryla-
tion of GFP-TDP220-414 may promote the formation of
insoluble inclusions thus rendering phosphorylated-
GFP-TDP220-414 resistant to degradation compared to its
non-phosphorylated counterpart (Figure 5). Consistent
with this, in vitro phosphorylation of recombinant full-
length TDP-43 by casein kinases was shown to enhance
TDP-43 oligomerization and fibrillization [14]. Ample
evidence also suggests that covalent modifications of
proteins, such as phosphorylation, facilitate protein
aggregation in various neurodegenerative diseases. For
example, studies report that phosphorylation of a-synu-
clein, ataxin-1 and tau regulates their aggregation and
inclusion formation [21-23].
Of particular interest, we found that knocking-down
Hsp90 or Hsp70 led to elevated levels of GFP-TDP220-414
and especially phosphorylated-GFP-TDP220-414 (Figure 4),
suggesting that chaperone-mediated degradation accounts,
at least in part, for the clearance of GFP-TDP220-414. This
is further supported by the fact that GFP-TDP220-414 binds
both Hsp70 and Hsp90, two molecular chaperones
involved in targeting client proteins for proteasome-
mediated degradation. Phosphorylated-GFP-TDP220-414
accumulated to a greater degree compared to total GFP-
TDP220-414 following Hsp70 or Hsp90 knockdown (Figure
5). Again, this may suggest that phosphorylated-GFP-
TDP220-414 is resistant to degradation, such that perturba-
tions in the mechanisms through which it is cleared cause
a more appreciable accumulation. However, the significant
accumulation of phosphorylated-GFP-TDP220-414 com-
pared to total GFP-TDP220-414 following Hsp70 or Hsp90
knockdown could also indicate that phosphorylated-GFP-
TDP220-414 is preferentially targeted by Hsp90 and Hsp70.
Indeed, the phosphorylation state of other proteins impli-
cated in neurodegenerative diseases is reported to influ-
ence their clearance; for instance, we have shown that
chaperone induction results in the selective proteasomal
degradation of specific phosphorylated and conformation-
ally altered tau species, while sparing tau phosphorylated
at different sites from being degraded [24].
Conclusions
In summary, the findings of the present study indicate:
1) Gradual expression of GFP-TDP220-414 within neuro-
blastoma cells leads to the formation of cytoplasmic
inclusions that are immunoreactive for both ubiquitin
and phosphorylated TDP-43; 2) At the time-points
examined, the inclusions are reversible and cleared pri-
marily through the UPS; 3) Phosphorylation of TDP-43
C-terminal fragments slows degradation and likely facili-
tates aggregation; and 4) Hsp70 and Hsp90 regulate
GFP-TDP220-414 degradation, such that knocking-down
Hsp70 or Hsp90 expression causes GFP-TDP220-414, and
especially phosphorylated-GFP-TDP220-414, to accumu-
late. Our findings provide novel insight regarding the
influence of phosphorylation on the degradation and
aggregation of TDP-43 C-terminal fragments. Because
phosphorylation may hinder TDP-43 degradation and
accelerate inclusion formation in disease, modulating
the phosphorylation state ofT D P - 4 3t r u n c a t i o np r o -
ducts may prove to be a promising therapeutic approach
to enhance clearance of TDP-43 inclusions. Indeed, it is
most promising that our results indicate that inclusions,
once formed, can be reversed. Our novel cell model pro-
vides an ideal tool for high-throughput screening of
small-molecule libraries for the identification of com-
pounds that diminish TDP-43 inclusions.
Methods
Plasmids
The GFP-tagged TDP-43 C-terminal fragments (GFP-
TDP208-414 and GFP-TDP247-414) were generated by PCR
to fuse GFP to the 5’ end of TDP-43. The primers were:
GFP-TDP208-414:5 ’-CGGGATCCATGCGGGAGTTCT
TCTCTCAGTACG-3’ and 5’-GCTCTAGACTACATT
CCCCAGCCAGAAGAC-3’;G F P - T D P 247-414:5 ’-CGG
GATCCGACTTGATCATTAAAGG-3’ and 5’-GCTCT
AGACATTCCCCAGCCAGAAGAC-3’.T h eP C Rp r o -
duct was subcloned into the pEGFP-C1 vector (Clon-
tech) using restriction sites BamHI and XbaI.
The pTRE-GFP-TDP208-414, pTRE-GFP-TDP2220-414,
pTRE-GFP-TDP247-414, pTRE-GFP-TDP-43 or pTRE-GFP
plasmids were constructed by cloning cDNA into the
pTRE vector using SacII and XbaI restriction sites.
Because the SacII restriction site was present within the
GFP-TDPX-X cDNA, site-directed mutagenesis (Strate-
gene) was used to eliminate the SacII site using the follow-
ing primers: 5’-GAATTCTGCAGTCGACGGTA CAGCA
GGCCCGGGATCCATG-3’ and 5’-CATGGAT CCCGGG
CCTGCTGTACCGTCGACTGCAGAATTC-3’.A f t e r -
wards, the pTRE-GFP-TDPX-X plasmids were generated
using primers 5’-TCCCCGCGGCGCCACCATGGTGAG-
CAAG-3’ and 5’-GCTCTAGACTACATTCCCC AGCCA-
GAAGAC-3’. The pTRE-GFP plasmid was generated by
using the primers: 5’-TCCCCGCGGCGCCACCATGGT-
GAGCAAG-3’ and 5’-GCTCTAGACTACTT GTA-
CAGCTCGTCCATG-3’.T h ep T R E - G F P - T D P X-X or
pTRE-GFP plasmids conditionally express GFP-tagged
full-length TDP-43, TDP-43 C-terminal fragments or GFP
upon removal of doxycycline from the media.
Transient Expression of TDP-43 C-terminal Fragments
To detect if various TDP-43 C-terminal fragments share
similar pathological features in cells, M17 founder cells
were grown in 24-well or 6-well plates in Opti-Mem
supplemented with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin. When cells reached 90%
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well plate) or 1 μg/well (6-well plates) of plasmid using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. After 48 h, the cells were fixed
for confocal analysis or harvested for Western blot
analysis.
Generation of Stable Human Neuroblastoma M17 Cell
Lines Conditionally Expressing GFP-TDP220-414
The human neuroblastoma M17 D tetracycline off (Tet-
Off) founder line has previously been described [25].
M17 D cells were grown in Opti-Mem supplemented
with 10% FBS, 1% penicillin/streptomycin, 400 μg/ml
G418 and 1 μg/ml doxycycline. For transfection of the
pTRE-GFP-TDP220-414 plasmid, M17 D cells were
seeded in a 10 cm dish. Once 90% confluency was
reached, cells were cotransfected with 5 μg pTRE-GFP-
TDP220-414 and 0.5 μg PVGRX (zeocin-resistant gene)
by using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Forty-eight hours after
transfection, the cells were suspended in 5 ml medium,
and then suspended cells were diluted 1000 times and
seeded in a 10 cm dish. Twenty-four hours later,
100 μg/ml zeocin was added to the medium to screen
for clones resistant to zeocin. After incubating cells for
10 days, single clones were picked and seeded into a 24-
well plate. When the cell confluency reached ~80%,
each clone was split into duplicate wells and cells were
grown in Opti-Mem supplemented with 10% FBS, 1%
penicillin/streptomycin, 400 μg/ml G418, 1 μg/ml doxy-
cycline and 100 μg/ml zeocin. When cell confluency
reached ~80%, doxycycline was removed from one of
the duplicate wells to induce transgene expression.
Inclusion formation was monitored by fluorescence
microscopy. The clone M17D3 was chosen and used
throughout the study.
Cell Treatments
To examine inclusion formation by confocal microscopy
and to assess GFP-TDP220-414 protein expression by
Western blotting, M17D3 cells, seeded at 6.0 × 10
4 cells
per well in 24-well plates or at 2.4 × 10
5 cells per well in
6-well plates, were grown in culture medium in the pre-
sence of 1 μg/ml doxycycline to inhibit GFP-TDP220-414
expression or in the absence of doxycycline to induce
GFP-TDP220-414 expression. Cells were fixed or harvested
at the indicated time-points for confocal microscopy and
Western blot analysis, respectively.
To determine whether inclusions formed during GFP-
TDP220-414 expression can be degraded when protein
expression is arrested, GFP-TDP220-414 was inducibly
expressed for 5 days. On day 5, 1 μg/ml doxycycline was
added to the culture medium to halt GFP-TDP220-414
expression. Also added was 10 μM MG-132 (proteasome
inhibitor), 50 μM chloroquine (lysosome inhibitor),
10 mM NH4Cl (lysosome inhibitor) or 10 mM 3-MA
(autophagy inhibitor). On day 6, cells were fixed or har-
vested for confocal microscopy and Western blot analy-
sis, respectively.
To determine the half-life of GFP-TDP220-414,i t s
expression was induced for 5 days, at which point 1 μg/
ml doxycycline was added to the medium to halt trans-
gene expression. Cells were harvested at 0, 6, 12, 18 or
24 hours after the addition of doxycycline for Western
blot analysis.
To confirm that degradation of GFP-TDP220-414 is not
simply due to targeted degradation of the GFP tag, M17
founder cells seeded in 6-well plates were transfected
with 0.5 μg of pTRE-GFP-TDP220-414 or pTRE-GFP
plasmid in the presence or absence of 1 μg/ml doxycy-
cline. Twenty-four hours after transfection, 1 μg/ml
doxycycline (with or without 10 μM MG-132) was
added to the culture medium and cells were harvested
for Western blot analysis 24 hours later.
To determine if Hsp90 or Hsp70 knockdown affects
GFP-TDP220-414 degradation, their expression was
reduced by using small interfering RNA (siRNA). Briefly,
M17D3 cells, seeded at 2.4 × 10
5 cells per well in 6-well
plates, were grown in doxycycline-free medium for 4
days. Then, 20 nM/well of siRNA (Hsp90, Hsp70 or a
validated negative control siRNA) was transfected into
cells using siLentFect transfection reagent (Bio-Rad)
according to the manufacturer’s instructions. After 48
hours, cells were harvested for Western blot analysis.
The siRNA was predesigned by Qiagen. The sense
sequence for each were: Hsp90 r(CCGACGAUAUUA-
CUAAUGA)dTdT; Hsp70 r(CCAUUGAGGAGGUA-
GAUUA)dTdT.
Immunofluorescence
To determine if inclusions composed of C-terminal frag-
ments are ubiquitinated and phosphorylated, cells grown
on coverslips were fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS) at 4 °C for 15 min, and
then permeabilized with 0.5% Triton X-100 in PBS for
10 min. After blocking with 5% bovine serum albumin
for 1 h at 37 °C, the cells were incubated overnight at 4
°C with rabbit polyclonal ubiquitin antibody (1:100,
DakoCytomation) or rabbit polyclonal anti-pTDP-43
(which detects phosphorylated S409/S410; 1:1000,
Cosmo Bio Co. Ltd.). After washing, cells were incu-
bated with the Alexa 568-conjugated goat anti-mouse or
anti-rabbit IgG secondary antibody (1:1000, Molecular
Probes). Hoechst 33258 (1 μg/ml) was used to stain the
nuclei and images were obtained on a Zeiss LSM 510
META confocal microscope.
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For co-immunoprecipitation studies, M17 founder cells
were cotransfected with 0.5 μgH A - U b i q u i t i na n d1μg
GFP or GFP-TDP220-414. Cells were harvested 48 h later
using Co-IP buffer (50 mM Tris-HCl, pH 7.4, 1 M
NaCl, 1% Triton X-100, 5 mM EDTA) containing PMSF
as well as protease and phosphatase inhibitors. The
lysates were sonicated and centrifuged at 16,000 g for
20 min. The protein concentration of supernatants was
determined by BCA assay (Thermo Scientific). Superna-
tant containing 300 μg of total protein was pre-cleared
with 15 μl Protein G agarose (Pierce) for 30 min, then
incubated with rabbit polyclonal anti-GFP antibody (0.5
ul, Abcam) overnight at 4 °C with gentle shaking. Next,
15 ul Protein G agarose was added to capture the pro-
tein-antibody complex. Following a 6 h incubation at 4 °
C, the agarose was pelleted by centrifugation at 1, 000 g
for 3 min and washed with Co-IP buffer 6 times. Cap-
tured protein was eluted from the beads using sample
loading buffer and resolved by SDS/PAGE for Western
blot analysis.
Fractionation Assay
Briefly, cells were lysed in a buffer containing Co-IP buf-
fer plus PMSF and both a protease and phosphatase
inhibitor mixture. After sonication, cells were centri-
fuged at 16,000 g at 4°C for 20 min. Triton X-100-inso-
luble pellets were dissolved in the Co-IP buffer plus 1%
SDS, PMSF, and both a protease and phosphatase inhi-
bitor mixture. The soluble and insoluble fractions were
used for Western blot analysis.
Western Blot Analysis
Cells were lysed in lysis buffer consisting of Co-IP buffer
plus 1% SDS, PMSF, and both a protease and phospha-
tase inhibitor mixture. The protein concentration of cell
lysates was measured using a BCA assay (Pierce). Sam-
ples were heated in Laemmli’s buffer and equal amounts
of protein were loaded into 10-well 4-12% Bis-Tris gels
(Novex, Invitrogen). After transfer, blots were blocked
with 5% nonfat dry milk in TBST (TBS plus 0.1% Triton
X-100) for 1 h, and then blots were incubated with rab-
bit polyclonal cTDP-43 antibody (developed against resi-
dues 350-414 of TDP-43; 1: 2000, Abcam), rabbit
polyclonal GFP antibody (1:2000, Invitrogen), rabbit
polyclonal anti-pTDP-43 (which detects phosphorylated
S409/S410; 1:2000, Cosmo Bio Co. Ltd.), mouse mono-
clonal GAPDH antibody (1:10000, Biodesign), mouse
monoclonal Hsp70 antibody (1:1000, Stressgen), rabbit
polyclonal LC3B antibody (1:1000, Cell Signaling Tech-
nology) or rat monoclonal Hsp90 antibody (1:5000,
Stressgen) overnight at 4°C. Membranes were washed
three times for 10 min in TBST and then incubated
with donkey anti-rabbit, anti-mouse or anti-rat IgG
conjugated to horseradish peroxidase (1:5000; Jackson
ImmunoResearch) for 1 hour. Membranes were washed
three times each for 10 min, and protein expression was
visualized by ECL treatment and exposure to film. The
levels of total GFP-TDP220-414, phosphorylated-GFP-
TDP220-414, Hsp70 and Hsp90 were normalized to their
corresponding GAPDH bands to correct for protein
loading.
Statistics
Data from 3 separate experiments were analyzed by
1-way ANOVA, followed by Tukey’s posthoc analysis.
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